secwatch.observer — SEC 8-K summary
======================================

Issuer:     Grace Therapeutics, Inc. (GRCE)
CIK:        0001444192
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0000950170-23-021346
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Acasti Pharma appoints new CMO, VP Clinical Ops; terminates CFO and COOs; submits GTX-104 Phase 3 plan to FDA
--------------------------------------------------------------------------------

- Appointed Dr. R. Loch Macdonald as CMO, Carrie D'Andrea as VP Clinical Ops, Amresh Kumar as VP Program Mgmt; effective immediately or May 15.
- Terminated CFO Brian Ford (interim until June 30), COO Canada Pierre Lemieux, COO US George Kottayil; severance payments.
- Submitted full protocol for GTX-104 pivotal Phase 3 Safety Study to FDA; first patient dosing expected Q4 2023.
- Strategic realignment focuses on GTX-104; cash runway extended through Q2 2025; evaluating alternatives for GTX-102, GTX-101.
- Discontinuing Canadian operations, laying off substantially all workforce; rebuilding leaner US organization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1444192/000095017023021346/0000950170-23-021346-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1444192/000095017023021346/acst-20230508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-021346

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer